I76 Stock Chart & Stats
€3.28
€0.10(3.14%)
At close: 4:00 PM EDT
€3.28
€0.10(3.14%)
Day’s Range― - ―
52-Week Range€0.65 - €4.48
Previous CloseN/A
Volume0.00
Average Volume (3M)96.00
Market Cap
€603.78M
Enterprise Value€961.97
Total Cash (Recent Filing)€220.47M
Total Debt (Recent Filing)€597.36M
Price to Earnings (P/E)6.7
Beta1.02
Next Earnings
Aug 06, 2026EPS Estimate
0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.64
Shares Outstanding164,613,400
10 Day Avg. Volume0
30 Day Avg. Volume96
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-2.09
Price to Sales (P/S)1.85
P/FCF Ratio4.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.37Price Target Upside33.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.04
Revenue Forecast (FY)€405.33M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLinzess revenues of $248M for 2Q25 appear on track to meet guidance of $800-850M and reflect normalization of gross-to-net accounting fluctuations.
ProfitabilityIRWD also raised FY25 Adjusted EBITDA guidance by ~$20M to $105M+ driven by expectation of lower commercial spend related to the Apra launch.
Revenue GrowthPrescription demand growth continues to be strong with IRWD highlighting 8% y/y volume growth in 1Q25.
Bears Say
Debt ChallengesThe high debt load and delay in apraglutide's revenue contribution mean there will likely be no meaningful revenue contribution until after Linzess' loss of exclusivity and debt maturity.
Regulatory SetbacksThe launch of Apraglutide has been delayed to 2029, reflecting setbacks in the drug's development and approval process.
Stock OutlookThe price target has been reduced from $3.00 to $1.00, indicating a more cautious outlook on the stock.
Ironwood Pharma News
I76 FAQ
What was Ironwood Pharma’s price range in the past 12 months?
Ironwood Pharma lowest stock price was €0.65 and its highest was €4.48 in the past 12 months.
What is Ironwood Pharma’s market cap?
Ironwood Pharma’s market cap is €603.78M.
When is Ironwood Pharma’s upcoming earnings report date?
Ironwood Pharma’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were Ironwood Pharma’s earnings last quarter?
Ironwood Pharma released its earnings results on May 07, 2026. The company reported €0.208 earnings per share for the quarter, missing the consensus estimate of €0.215 by -€0.006.
Is Ironwood Pharma overvalued?
According to Wall Street analysts Ironwood Pharma’s price is currently Undervalued.
Does Ironwood Pharma pay dividends?
Ironwood Pharma does not currently pay dividends.
What is Ironwood Pharma’s EPS estimate?
Ironwood Pharma’s EPS estimate is 0.28.
How many shares outstanding does Ironwood Pharma have?
Ironwood Pharma has 164,613,400 shares outstanding.
What happened to Ironwood Pharma’s price movement after its last earnings report?
Ironwood Pharma reported an EPS of €0.208 in its last earnings report, missing expectations of €0.215. Following the earnings report the stock price went down -6.878%.
Which hedge fund is a major shareholder of Ironwood Pharma?
Currently, no hedge funds are holding shares in DE:I76
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ironwood Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.37 (33.09% Upside)
€4.37 (33.09% Upside)
Blogger Sentiment
Bullish
DE:I76 Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
379.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
32.81%
Trailing 12-Months
Company Description
Ironwood Pharma
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
I76 Company Deck
I76 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a predominantly positive outlook driven by strong LINZESS Q1 performance (97% YoY net sales growth), robust profitability (GAAP net income $40.8M; adjusted EBITDA $76.7M), healthy cash on hand, and clear progress toward initiating the STARS‑2 confirmatory trial for apraglutide with supportive efficacy and safety data. Key near‑term risks include the June convertible note maturity (reliance on receivable collection), anticipated R&D spend and enrollment risk for STARS‑2, and potential moderation of prescription growth later in 2026 (notably in Medicaid). Overall, the positive financial momentum and clinical progress outweigh the manageable execution and timing risks noted.View all DE:I76 earnings summariesI76 Stock 12 Month Forecast
Average Price Target
€4.37
▲(33.09% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Evotec AG
―
Collegium Pharmaceutical
―